Articles
We're so proud to be part of the successful CLEAR Outcomes trials by Esperion Therapeutics
The goal of the study was to determine if the investigational drug, Bempedoic acid, can reduce major cardiovascular events in patients with heart disease or at high risk who experienced complications from statin use. The results were presented at ACC.23 and published in the New England Journal of Medicine. Bempedoic acid proved to be significantly more effective in reducing heart-related events and coronary revascularisation compared to the placebo. These findings hold great promise for patients with cardiovascular disease who are intolerant to statins.
This accomplishment truly underscores the transformative power of medical research in improving public health.
For the last three years, Optimal Clinical Trials played a key role in ensuring the collection of high-quality data and participant retention for this study.
Thank you to our study sponsor, Esperion Therapeutics, and to IQVIA for their trust in Optimal Clinical Trials to be part of this groundbreaking research. It's an honour for our team to be working with you, for good.